Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer gov’t relations VP

This article was originally published in The Tan Sheet

Executive Summary

Anthony Principi will succeed Kenneth Bowler as Pfizer's VP-government relations, the firm announces March 7. Principi served as secretary of Veterans Affairs under President George Bush and deputy secretary of Veterans Affairs under George H. W. Bush; he spent 10 years in the private sector as president of QTC Medical Services, senior VP at Lockheed Martin IMS and partner at San Diego law firm Luce, Forward, Hamilton & Scripps...

You may also be interested in...



Pfizer Principi departure

Pfizer is seeking a new VP-government affairs following the resignation of Anthony Principi, the firm announces. Principi assumed his post March 15 (1"The Tan Sheet" March 15, 2005, In Brief). Principi headed the company's Washington, D.C. office and is leaving because of the time commitment required to fulfill his duties as chairman of the government's Base Realignment & Closure Commission, Pfizer said. The commission began work May 3. Pfizer Senior VP-Government Relations Richard Bagger, to whom the D.C. office head reports, will assume control of the government affairs staff until a replacement for Principi is found...

QUOTED. 29 September 2020. Phil Brown.

ABHI’s Phil Brown believes the future of UK device regulation will be innovation-friendly and patient-responsive system – but doesn’t expect easy alignment with the EU. See what he had to say.

COVID-19 Vaccines: HHS Advisory Committee Urges ‘Great Caution’ On Use Of EUA

Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel